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Abstract. 
Leprosy and podoconiosis (podo) are neglected tropical diseases that cause severe disfigurement and disability, and 
may lead to catastrophic health expenditure and hinder economic development of affected persons and households. 
This study compared economic costs of both diseases on affected households with unaffected neighboring 
households in the Northwest Region (N.W.R.) of Cameroon. A matched comparative cross-sectional design was 
used enrolling 170 households (43 podo case households, 41 podo control households, 43 leprosy case households, 
and 43 leprosy control households) from three health districts in the N.W.R. Direct treatment costs for podo 
averaged 142 United State dollar (USD), compared with zero for leprosy (P < 0.001). This was also reflected in the 
proportion of annual household income consumed (0.4 versus 0.0, respectively, P < 0.001). Both diseases caused 
considerable reductions in working days (leprosy 115 versus podo 135 days. P for comparison < 0.001). The 
average household income was considerably lower in podo-affected households than unaffected households (410 
versus 913 USD, P = 0.01), whereas income of leprosy-affected households was comparable to unaffected 
households (329 versus 399 USD, P = 0.23). Both leprosy and podo cause financial burdens on affected households, 
but those on podo-affected families are much greater. These burdens occur through direct treatment costs and 
reduced ability to work. Improved access to public health interventions for podo including prevention, morbidity 
management and disability prevention are likely to result in economic returns to affected families. In Cameroon, one 
approach to this would be through subsidized health insurance for these economically vulnerable households. 
INTRODUCTION 
Neglected tropical diseases (NTDs) are chronic, disabling, and disfiguring conditions 
commonly occurring in settings of extreme poverty, particularly in the rural poor and some 
disadvantaged urban populations.
1
 Neglected tropical diseases are both the consequence and 
cause of poverty. They are common among very poor individuals and they cause poverty, 
through stigma, disability, and reduced productivity. The world’s greatest concentration of 
poverty occurs in sub-Saharan Africa (SSA). The World Bank analyzed 51% of the population of 
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SSA as living on less than 1.25 United State dollar (USD) per day, and 73% of the population 
living on less than 2 USD per day.
2
 Leprosy and podoconiosis (podo) are diseases that hinder 
economic development and cause chronic life-long disability in the poor and disenfranchised 
communities in which they are most prevalent. 
Podoconiosis (endemic nonfilarial elephantiasis) is a noninfectious geochemical disease 
caused by the conjunction of environmental, genetic, and economic factors.
3
 This condition, 
which has been categorized as an environmental geochemical disease resulting from irritant soil, 
occurs in individuals who have been exposed to red clay soil derived from alkaline volcanic 
rock.
4
 Podoconiosis has been reported among barefoot farmers in volcanic highland zones of 
Africa, Central and South America, and northwestern India.
4
 In Cameroon, podo was first 
described in 1981 by Price.
5
 An estimated 500,000 persons are affected with podo in the 
highland zones of Cameroon.
4
 Despite the public health importance of the disease, it has 
received little attention from policy makers in Cameroon. This may partly be because of the 
absence of data on the economic impact of the disease in this country. 
The disease is characterized by bilateral swelling of the lower legs with mossy and nodular 
changes to the skin.
6
 Podoconiosis follows a chronic course, with progressively increasing 
disability, especially with continued exposure to irritant soils. However, with simple treatment, 
the condition is reversible. The disability and deformity caused by podo have been shown to 
have economic consequences
7
 just like leprosy.
8
 
Leprosy, also known as Hansen’s disease, is a chronic infectious disease caused by a slow-
growing bacterium called Mycobacterium leprae. From the World Health Organization’s end of 
first quarter 2017 reports, 171,948 cases were registered as receiving multidrug therapy, with a 
registered prevalence rate of 0.23 per 10,000 population
7
 from 143 countries.
9
 The Americas and 
southeast regions registered the highest number of leprosy cases. A total of 214,783 new cases 
were reported from 143 countries during 2016, corresponding to the global new-case detection 
rate of 2.9 per 100,000 population.
9
 
Although leprosy has been eliminated as a public health problem in Cameroon, there are still 
areas with high prevalence such as Essimbiland (Menchum Division) with a prevalence of 
4.5/10,000 and Mbingo (Boyo Division) with a prevalence of 3.5/10,000 in the Northwest 
Region (N.W.R.).
10
 
Leprosy affects mainly the skin and peripheral nerves. Its diagnosis is established based on 
skin and neurologic examination of the patient.
11
 Without early diagnosis and treatment, leprosy 
progressively results in physical disabilities.
11
 It is highly contagious, but its morbidity is low 
because a large portion of the population is naturally resistant to this disease. Transmission has 
been associated with close and repeated contact with nose and mouth droplets from untreated 
leprosy patients, and children are more likely to contract the disease than adults. 
Both podo and leprosy are diseases associated with devastating disabilities which are likely 
to interfere with economic and domestic (household chores and leisure) activities, thereby 
reducing such patients’ ability to attain good health.12 According to a study conducted in 
Ethiopia,
7
 the economic costs of podo in Ethiopia are high, with direct treatment costs being 
equivalent to 143 USD per patient per year. In addition, the physical challenges of the condition 
contribute to large productivity losses as most of the patients are of working age.
13
 Given the 
lack of evidence around the economic impact of podo, the Cameroon government has prioritized 
diseases with clearer evidence of economic and development impact such as leprosy. There is 
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therefore a need for evidence-based research focusing on the treatment costs and cost burden of 
podo to fill the gap in the scientific literature. Quantifying the economic impact of podo and 
comparing this with the impact of leprosy will help underscore the public health importance of 
podo. 
MATERIALS AND METHODS 
Study design. 
The study used a matched comparative cross-sectional study design to estimate the yearly 
household income and expenditures associated with treatment of diseases (podo, leprosy, and 
other common conditions) for both affected and unaffected households. A comparative design 
was used to compare the economic cost of disease between podo- and leprosy-affected 
households. A semistructured questionnaire was used for data collection documenting economic 
characteristics of households. 
Study area. 
The N.W.R. of Cameroon has 19 health districts with the Batibo and Ndop health districts 
being the most affected with podo (Wanji et al., unpublished data). The population of Batibo and 
Ndop practice high levels of subsistence agriculture, which is the main economic driver within 
both communities. The Ndop plain is known in the region for the cultivation of rice in marshy 
wetlands. These agricultural factors predispose the inhabitants to the risk of acquiring podo due 
to continuous exposure of bare feet to the soil. The Mbingo Baptist leprosarium is one of the 
oldest leprosaria in Cameroon and is in the Fundong health district within the Mejang health 
area. A good number of leprosy resident households are found in this area owing to referrals 
from other regions of the country to this leprosarium. Data collection spanned from July to 
August 2015 within these areas. 
Sampling and study subjects. 
Batibo and Ndop health districts were purposively chosen for known high prevalence of podo 
in previous studies conducted within the N.W.R.
4
 Households with confirmed podo cases living 
in communities within Batibo and Ndop health districts were sequentially selected from a list of 
confirmed cases from an earlier prevalence study. Leprosy patients (currently on treatment or 
treated in the past) living within communities in Mejang health area were sequentially selected 
from the Mbingo leprosarium register. 
Participants consisted of podo and leprosy cases in the most affected and economically active 
age group (15 years and older) regardless of coexistence of any other disease because economic 
cost of other diseases was assessed in this study to control for confounders. Controls were 
individuals from households unaffected by podo or leprosy within the communities of interest. 
These individuals were matched to cases by age (±5 years), gender, and occupation, and enrolled 
in a 1:1 case:control ratio. 
Variables and cost estimation. 
The prevalence-based model, which quantifies economic costs due to illness occurring within 
a given time period
13
 (1 year in this study), was used from the societal perspective. Variables for 
measurement included household annual income, annual economic cost of treatment, and cost 
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burden of diseases for both case and control households. Economic costs were estimated in terms 
of direct and indirect health costs. Indicators for direct (out-of-pocket) costs and indirect 
(productivity loss) patient costs were defined, and for analytic purposes, direct costs were 
divided into categories (Table 1). In this study, direct costs were defined as the medical and 
nonmedical costs of receiving health care for both patients and accompanying persons. Indirect 
costs were measured in terms of productive time lost (converted into cost based on the hourly 
gross income of each household yearly). 
The aforementioned economic variables were estimated for commonly occurring diseases 
and for leprosy or podo for case households, but for commonly occurring diseases only for 
control households. 
Household earnings were estimated based on the combined salaries of household members 
participating in the study over the last month and extrapolated to a calendar year, plus the total 
annual agricultural products multiplied by average market price, to give an annual per household 
sum. 
Instrument for measurement. 
Assessment methods for both case and control households were the same to allow 
comparison between groups. For both case and control households, a semistructured 
questionnaire was used to establish sociodemographic and economic characteristics of the 
household such as direct health cost and economic productivity loss. The questionnaire 
documented the following: 
Sociodemographic characteristics (age, gender, level of education, number of household members, and marital 
status) of the case or control individual; 
Yearly income of households (estimated as described previously, and using a list of agricultural products typical 
of the community); 
Direct payments for nonmedical items such as transportation, lodging, and food for patients and accompanying 
persons; 
Direct costs incurred for biomedical and medical items which includes professional time, treatment, and 
overheads in and outside the health facility,
14
 including traditional healers; 
Cost of lost productivity referring to the value of foregone earnings from economic activities as the result of 
working fewer hours during illness than healthy matched individuals. 
An open-ended question was used to estimate other aspects of costing such as gifts resulting 
from illness, extra phone calls, and extra food from home to treatment site for patient and 
caretakers. 
Patients and their caretakers were asked to estimate their daily hours of work when well and 
when unwell, to estimate the number of productive hours lost by patients and caretakers because 
of illness. This was then converted to cost by multiplying the household hourly income 
(calculated from the annual household income) and the total number of productive hours lost. 
Efforts were made to reduce the possibility of recall bias by prompting questions from monthly 
average estimates, then to yearly estimates. 
Households as unit of measurement. 
We took the household as the unit of measurement for several reasons. First, the household is 
the basic economic unit when coping with the illness costs of its members. Second, decisions 
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about treatment are based on negotiations within the household (although not necessarily from an 
equal bargaining position). Third, the costs of illness reach beyond the sick to involve other 
household members who care for them and accompany them to seek treatment. 
Data analysis. 
The variables from this quantitative study were precoded and data computerized using Epi 
Info v.3.5 (CDC, Atlanta, GA) and imported to SPSS v.20 (IBM Corp., Armonk, NY) for 
analysis. The 2 test was used to establish sociodemographic differences between case and 
control groups. The Kolmogorov–Smirnov test was used to determine mean differences in 
number of working days lost between case and control households and the normality of the 
distribution. The Mann–Whitney U test of significance was used to determine differences in 
income status and proportions of health burden between study groups for data not normally 
distributed owing to outliers. 
Ethical consideration. 
Ethical approval was obtained from the University of Buea, Faculty of Health Science 
Institutional Review Board and the Bamenda Regional Hospital Institutional Review Board after 
a departmental authorization was issued from the University of Buea. Regional and 
administrative clearances were obtained from the North West Regional Delegation of Public 
Health and from district medical officers of health districts. Permission was equally obtained 
from the Cameroon Baptist Convention (CBC) Health Service to collect data at the Mbingo 
Baptist hospital. Written informed consent forms were used to ensure participants’ willingness to 
participate in the study using methods described by Kengne-Ouafo et al.
15
 from their study on 
perceptions of consent, permission structures, and approaches to the community in Northwest 
Cameroon. 
RESULTS 
Basic characteristics of participants. 
The study enrolled a total of 170 households, 43 affected by podo (and 43 control households 
matched to the podo proband) and 43 affected by leprosy (and 41 control households matched to 
the leprosy proband). The discrepancy in cases and controls for leprosy was because of the fact 
that matched controls for two leprosy patients with respect to gender, age, and occupation could 
not be found. 
The study had an approximate distribution of gender as follows: 48.8% of leprosy cases and 
controls were female, whereas 48.8% of podo cases and 46.3% of podo controls were female 
(Table 2). The age of podo participants ranged from 30 to 87 for cases and from 26 to 85 for 
controls with a mean (standard deviation [SD]) age of 59 (16.8) and 58 (17.3) years for cases and 
controls, respectively. The age range of leprosy participants was from 27 to 87 for cases and 
from 25 to 90 for controls with a mean (SD) age of 61 (16) and 61 (15.6) years cases and 
controls, respectively. Of the 170 respondents, 5.3% (9) attained higher education, 9.4% (16) had 
secondary education, 58.8% (100) had First School Leaving Certificates, 24.7% (42) did not 
attain any education, and 1.8% (3) attended other informal educational setups such as adult 
school and some vocational training. 
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The marital status among participants showed 13.6% (23) to be single, 55.6% (94) married, 
24.9% (42) widows, and 5.9% (10) divorced, with fewer podo patients and leprosy patients being 
married than their controls. Christianity was the leading religion among participant households 
for both diseases and their controls. 
Household income, direct and indirect cost of common household diseases. 
The average household income for leprosy case households was 329 USD and 399 USD for 
control households (P > 0.05) (current exchange rate (September 10, 2015; 1 USD = 586 FCFA). 
On the other hand, the yearly average income for podo case household was 410 USD and 913 
USD for control households (P < 0.05). 
Table 3 shows that podo case households spent 33% of their annual income on treatment of 
commonly occurring diseases, whereas the equivalent figure for control households was 13% (P 
< 0.05). Leprosy case households spent 6% of their annual income and control households 12% 
on treatment of these common diseases. A mean of 36 and 23 working days were lost each year 
for leprosy case and control households, respectively, with a statistical value of P < 0.05 (95% 
confidence interval [CI], Kolmogorov–Smirnov test). The working days lost accounted for an 
average household income loss of 6 USD for case households and 11 USD for control 
households (P > 0.05, 95% CI, Mann–Whitney U test). A mean of 54 and 47 working days were 
lost annually for podo case and control households, respectively, because of commonly occurring 
diseases (P > 0.05, 95% CI). This loss amounted to a yearly average household income loss of 12 
USD for case households and 18 USD for control households (P > 0.05, 95% CI). 
Direct and indirect cost of podo and leprosy on affected households. 
Podoconiosis patients spent an average of 137 USD out of pocket on medical treatment of the 
disease, whereas leprosy patients spent almost nothing for treatment (P < 0.05, 95% CI, Mann–
Whitney U test). Within the nonmedical cost category, podo patients spent a total average cost of 
9 USD for transportation, extra food, and rent, whereas leprosy patients spent approximately 0 
USD (P < 0.05, 95% CI). For miscellaneous costs, podo patients spent an average sum of 9 USD 
for extra phone calls because of disease and extra food for patients and caretakers. Leprosy 
patients on the other hand, spent almost nothing for calls and food, (P < 0.05). 
Overall, podo patients spent an average of 142 USD annually for direct out-of-pocket 
treatment of podo, whereas leprosy patients spend almost nothing, P < 0.05. Podoconiosis 
patients incurred an annual debt of 34 USD for treatment of podo, thus, 34 USD of the 142 USD 
spent per annum is money borrowed from friends, family, or community groups which was not 
the case for leprosy households. At 34.7% of annual income, average out-of-pocket expenditure 
for podo households clearly exceeded the level defined as catastrophic health expenditure (> 
10% of income). 
A total of 115 working days were lost for leprosy and 135 days for podo over the past year (P 
< 0.05, Kolmogorov–Smirnov test) (Table 4). These lost days accounted for an annual total loss 
of 26 USD and 40 USD for leprosy and podo households, respectively (P < 0.05, 95% CI, 
Mann–Whitney U test). 
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Economic cost and cost burden of podo and leprosy. 
The annual economic cost of leprosy amounted to a total of 26 USD, whereas that of podo 
was 203 USD (P < 0.05, 95% CI, Mann–Whitney U test) (Table 4). Forty percentage of annual 
household income was used for podo treatment in podo households, whereas almost no 
household income was used for leprosy treatment (P < 0.05, 95% CI). 
DISCUSSION 
This study quantifies the economic burden of leprosy and podo in the N.W.R. of Cameroon. 
Podoconiosis leads to significant financial consequences on affected households, through direct 
and indirect treatment costs, whereas leprosy has a smaller, but still important, financial impact. 
In addition, both diseases cause significant loss of productive days per annum. Given the World 
Bank definition of catastrophic health expenditure as out-of-pocket expenditure of > 10% 
monthly income,
16
 our findings show that households affected by podo do experience 
catastrophic health expenditure, which is likely to cause further impoverishment, indicating the 
importance of prioritizing podo in the national NTD plan in order that affected households may 
benefit from schemes such as subsidized health insurance so they are better financially protected. 
Median annual income of podo case households was significantly lower than that for control 
households. This difference is explained by the fact that the disability associated with podo 
renders those affected less economically productive, hindering the capability of affected persons 
to increase their income to match that of their unaffected controls. This result agrees with Tekola 
et al.
7
 who stated that the disability associated with podo has devastating negative effects on 
households’ economic productivity. On the other hand, leprosy case households’ annual income 
was not significantly different from that of control households. This finding is not consistent 
with earlier data on the effects of erythema nodosum leprosum reactions on affected households. 
This may be explained by the fact that leprosy has been well addressed by the CBC, which 
provides patients with monthly salaries for skilled and unskilled labor within the facility and also 
provides monthly allowances and food for the most disabled patients, thereby increasing their 
consumption of other goods and services. 
The direct costs of commonly occurring household diseases in podo case and control 
households were similar at 147 USD and 142 USD, respectively. However, podo-affected 
households spend an extra 142 USD out of pocket yearly on podo; thus, podo-affected 
households spend an average of 288 USD annually, considerably higher than that spent by 
control households. These findings are comparable with the studies conducted in Ethiopia
7
 as 
follows: the direct costs in our study were 142 USD, whereas they were 143 USD in Ethiopia in 
2006. They were different with the costs of Buruli ulcer treatment at Akonolinga in Cameroon,
14
 
where direct out-of-pocket costs of treatment constituted 71 USD, which was catastrophic at the 
household level and consistent with our findings. 
Annually, 36 USD and 76 USD, respectively, was spent on direct costs of common 
household diseases by leprosy-affected and control households. Leprosy case households did not 
incur extra health expenditure for leprosy treatment because there is free treatment, 
rehabilitation, and food for leprosy patients and families within the treatment center. This is in 
contrast to the large amounts spent by podo households for treatment of the disease; thus, a 
statistically significant difference was observed in household direct costs between podo and 
leprosy. 
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Podoconiosis-affected households experienced average indirect costs of 40 USD annually 
(representing 135 lost working days), whereas leprosy-affected households experienced average 
indirect costs of 26 USD (representing 115 working days). The overall costs (direct and indirect) 
to podo- and leprosy-affected households were 203 USD and 26 USD per annum, respectively. 
Podoconiosis-affected households suffered both out-of-pocket payments for treatment of the 
disease and indirect disability costs because of loss of economic productivity, whereas leprosy-
affected households suffered only the disability costs associated with leprosy. One explanation 
for this difference is that leprosy has been incorporated into the national NTD control program 
and is also taken care of by other NGOs and missionary movements such as the CBC (the 
owners of Mbingo Baptist Hospital). 
At 40%, the proportion of annual household income consumed for treatment of podo is 
considerably higher than the World Bank threshold for catastrophic health expenditure. It is 
higher than the cost burden of Buruli ulcer treatment in Cameroon (25% of household income),
14
 
and comparable to that observed among leprosy-affected households in rural India (40% of 
household income).
8
 
This study has several strengths; first, the study used comparison groups including 
households affected by podo or leprosy and unaffected neighboring households. This strengthens 
the comparison of costs incurred in different categories. Second, we have assessed both direct 
and indirect cost of both diseases, which enables a broader picture of their economic effects to be 
developed. There were, however, some limitations: household diseases were limited to those 
commonly occurring annually in a household. This was carried out to reduce overestimation of 
average household cost of diseases within the community. Indirect costs were calculated based 
on household hourly income and not per patient hourly income and so may be overestimated. 
Productivity costs were limited to economic activities, and domestic productivity was not 
included in the cost estimation. Number of school days lost because of disease was not captured 
in this study. Family income for farmers was estimated based on quantity of commodities 
produced and sold, but very few of the farmers can give a robust estimate of the exact quantities 
of commodities produced. It is worth noting that, the scope of this study was limited to leprosy 
patients’ resident at the leprosarium. Therefore, the direct costs of leprosy treatment observed in 
this study truly reflects situations under a control scheme but, might not be a true representation 
in the population where patients not benefiting from control schemes are anticipated to spent 
money for their treatment. 
CONCLUSION 
Given the catastrophic out-of-pocket expenditure on treatment of podo in affected families, 
and the prevalence of the condition,
4
 health policy in Cameroon must prioritize prevention and 
treatment interventions for these households and communities. This study suggests that the 
economic effects of leprosy have been partly mitigated by government and nongovernment 
provision of treatment and rehabilitation services to patients and their families who no longer 
suffer catastrophic health expenditure to access treatment. Similar provision is urgently needed 
for podo patients. Models of disease management for people with podo have been tested in other 
low-resource settings, whereas disability inclusion models can be adapted from those used so 
successfully for people with leprosy. We call on the government of Cameroon to prioritize 
podo—to prevent new disease and disability and to ensure financial risk protection for affected 
households. 
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FIGURE 1. Case–control study design showing health cost assessment method for podoconiosis and leprosy. 
Common diseases referred to diseases of which every household within the community was likely to observe an 
episode yearly. This figure appears in color at www.ajtmh.org. 
TABLE 1 
Categories for cost assessment 
Cost type Cost category Definition 
Direct costs (out-
of-pocket 
payments) 
Biomedical expenses 
and hygiene costs 
These costs were related to patients’ personal hygiene when taking care of 
the wounds (e.g., bleach and soap to wash bandages and clothing), irregular 
expenses for extra medication (e.g., for pain relief), and official fees during 
treatment. 
Food, lodging, and 
transportation costs 
Food costs included extra meals taken at local food stands by patients or 
caretakers. Transportation costs refer to the costs of transport for the 
patient, caretaker(s), and other household members when traveling to and 
from the hospital to visit the hospitalized patient or when seeking care. 
Lodging costs included extra rent in the location of the hospital for 
caretakers. 
Miscellaneous costs These included a variety of non-systematic costs such as extra phone calls, 
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debts to community workgroups due to illness, gifts to hospitalized 
patients, extra food from home to hospital, etc. 
Indirect costs 
(disability) 
Productivity loss 
Productivity loss was based on the calculation of the individual’s (patient 
and/or caretaker) earnings per calendar year and the percentage of these 
earnings that was lost because of the morbidity and disability time caused 
by illness episode or caretaking. 
TABLE 2 
Basic characteristics of participants 
Variable Category 
Podoconiosis participants 
(n = 84) 
Leprosy participants (n = 
86) 
Cases 
(%) 
Controls 
(%) 
P 
valu
e 
Cases 
(%) 
Controls 
(%) 
P 
valu
e 
Gender 
Male 
22 
(51.2) 
22 
(53.7) 
NS 
22 
(51.2) 
22 
(51.2) 
NS 
Female 
21 
(48.8) 
19 
(46.3) 
21 
(48.8) 
21 
(48.8) 
Age 
(years) 
Mean 
(SD) 
59 
(16.8) 
58 
(17.3) 
NA 
61 (16) 
61 
(15.6) 
NA Range 
(Min.–
Max.) 
57 (30–
87) 
59 (26–
85) 
60 (27–
87) 
65 (25–
90) 
Literacy 
level 
Higher 3 (7.0) 4 (10.0) 
NS 
1 (2.3) 1 (2.4) 
NS 
Secondary 4 (9.3) 3 (7.5) 3 (7.0) 6 (14.6) 
Primary 
23 
(53.5) 
29 
(72.5) 
25 
(58.1) 
23 
(56.1) 
None 
13 
(30.2) 
4 (10.0) 
14 
(32.6) 
11 
(26.8) 
Marital 
status 
Single 3 (7.0) 3 (7.3) 
NS 
10 
(23.3) 
7 (16.7) 
NS 
Married/in 
union 
23 
(53.5) 
30 
(73.2) 
15 
(34.9) 
26 
(61.9) 
Divorced/s
eparated 
3 (7.0) 1 (2.4) 6 (14.0) 0 (0.0) 
Widowed 
14 
(32.6) 
7 (17.1) 
12 
(27.9) 
9 (21.4) 
Religion Christian 
43 
(100) 
41 (100) NA 
43 
(100) 
42 (100) NA 
Max. = maximium; Min. = minimium; n = total sample size; NA = not applicable; NS = not significant; SD = 
standard deviation; % = percentage. Level of significance = 5%; 95% confidence interval. 
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TABLE 3 
Household income, direct and indirect cost of common household diseases 
Variable 
Leprosy respondents (n) = 86 Podoconiosis respondents (n) = 84 
 n Median ± SD P value n Median ± SD P value 
Household income 
Controls 43 399 (1,146) 
NS 
41 913 (1,120) 
0.005 
Cases 43 329 (556) 43 410 (1,194) 
Total direct cost 
common diseases 
Controls 43 76 ± 91 
NS 
40 142 ± 189 
NS 
Cases 43 36 ± 75 42 147 ± 183 
Total 86 56 ± 83 – 82 145 ± 186 – 
Cost burden 
(fraction of 
household income 
consumed) (%) 
Controls 43 12 ± 78 
NS 
41 13 ± 55 
0.006 
Cases 43 6 ± 81 42 33 ± 348 
   Mean   Mean  
Working days lost 
to common 
diseases 
Controls 43 23 ± 19 
0.021 
41 47 ± 53 
NS 
Cases 43 36 ± 37 41 58 ± 52 
   Median   Median  
Total indirect cost 
of common 
diseases 
Controls 43 11 ± 26 
NS 
41 18 ± 38 
NS 
Cases 43 6 ± 14 41 12 ± 24 
Total 86 9 ± 20 – 82 15 ± 31 – 
n = sample size; NS = not significant; SD = standard deviation; % = percentage; 95% confidence interval. 
* P value < 0.05. 
† All cost was measured in United State dollar. 
TABLE 4 
Direct and indirect cost of podo and leprosy on affected households 
Cost categories Leprosy (median ± SD) Podo (median ± SD) P value 
Direct medical costs 0.00 ± 8 137 ± 488 < 0.001 
Direct nonmedical costs 0.00 ± 0.13 9 ± 24 < 0.001 
Miscellaneous 0.00 ± 0.34 9 ± 18 < 0.001 
Total direct costs 0.00 ± 8 142 ± 517 < 0.001 
Amount borrowed 0.00 ± 8 34 ± 489 < 0.001 
 Mean ± SD Mean ± SD  
Working days lost 115 ± 62 135 ± 106 < 0.001 
 Median ± SD Median ± SD  
Total indirect costs 26 ± 45 40 ± 124 NS 
Annual economic cost (direct and indirect) 
of podo/leprosy 
26 ± 45 203 ± 559 < 0.001 
Fraction of household income consumed 
yearly (cost burden) (%) 
0 ± 4 40 ± 303 < 0.001 
NS = not significant; Podo = podoconiosis; SD = standard deviation; % = percentage; 95% confidence interval. 
* P value < 0.05. 
† All costs were measured in United States dollar. 
‡ Sample size was 86 (43 podo and 43 leprosy). 
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